Robert Bok, MD, PhD

Valparaiso University, Valparaiso, IN, B.S., 1980, Biology and Chemistry
University of Illinois, Champaign-Urbana, IL, Ph.D., 1984, Biochemistry
John Hopkins University, Baltimore, MD, M.D., 1989, Medicine
University of Minnesota, Minneapolis, MN, Residency, 1992, Internal Medicine
University of California, San Francisco, Fellow, 1996, Hematology-Oncology

• 1980-84
  Biochemical studies on the regulation of plasminogen activation by fibrin and lysine-binding sites, University of Illinois, Biochemistry Department. Advisor: Walter Mangel, Ph.D.- As Graduate Student
• 1984-85
  Studies on the distribution of ubiquitin, a regulator of intracellular proteolysis, in biological systems, St. Jude Children's Research hospital, Memphis, TN. Advisor: Victor Fried, Ph.D. -- as Post-Doc
• 1985-86
  Summer research project on evaluation of small molecule serine protease inhibitor in cell culture system, Children's Hospital, university of Southern California, Los Angeles, CA Advisor: Walter Laug, M.D. -- as Medical Student
• 1987
  Research elective studying inhibition of tumor angiogensis by the antibiotic minocycline, Johns Hopkins Hospital, Brain Tumor Lab, Baltimore MD. Advisor: Henry Brem, M.D. -- as Medical Student
• 1988
  Research elective investigating serum of patients with Thrombotic Thrombocytopenic Purpura (TTP) for potential anti-endothelial cell auto-antibodies, Johns Hopkins Hospital, Hematology Division, Baltimore, MD. Advisor: William Bell M.D. -- As Medical Student
• 1990
  Research honors rotation studying the effect of HSB on Plasminogen Activator Inhibitor -- 1 (PAI-1) expression by endothelal Cells, University of Minnesota, Hematology Division, Dept. of Medicine, Minneapolis, MN. Advisor: Greg Vercellotti, M.D. -- As Medical Resident
• 1992-96
  Isolation and characterization of genomic fragments of the murine beta3 integrin gene for purposes of homologous recombination, Hematology-Oncology Division, Univ. of Calif., San Francisco. Advisor: Marc Shuman, M.D. -- As Hematology-Oncology Fellow
• 1996-98
  Characterization of integrins in basal cells of prostatic epithelium; Targeting of recombinant proteins to platelet granules via Dodecapeptide sequence, Hem.-Onc. Div., UCSF. Advisor: Marc Shuman, M.D. -- As Visiting Post-Doc
• 1998-2000
  Clinical Instructor, Urological Oncology Program, UCSF/Mt. Zion Cancer Center, San Francisco, CA. Assistant Clinical Professor appointment pending. Establishment of TRAMP transgenic mouse colony and protease expression analysis in conjunction with the Protease Project Group at UCSF.

• Bok, R.A. (1984) The Role of the Plasminogen-Fibrin Interaction in the Regulation of Fibrinolysis. Ph.D. Thesis, University of Illinois at Urbana-Champaign.
• Bok, R.A., and Mangel, W.F. (1985) Quantitative Characterization of the Binding of Plasminogen to Intact Fibrin Clots, Lysine-Sepharose, and Fibrin Cleaved by Plasmin. Biochemistry 14: 3279-86.
• Tamargo, R.F., Bok, R.A., and Brem, H. (1990) Angiogenesis Inhibition by Minocycline. Cancer Research 51(2): 672-75.
• Bok, R.A., Jacob, H.S., Balla J., Juckett, M., Stella, T., Shatos, M.S., and Vercellotti, G.M. (1993) Herpes Simplex Virus Decreases Endothelial Cell Plasminogen Activator Inhibitor. Thrombosis & Haemostasis 69(3): 253-58.
• Small, E.J., Baron, A., and Bok, R. (1997) Simultaneous Antiandrogen Withdrawal and Treatment with Ketoconazole and Hydrocortisone in Patients with Advanced Prostate Carcinoma. Cancer 80:1755-9.
• Bok, R.A., Hansell, E., McKerrow, J., Greenberg, N., and Shuman, M. Proteases in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model. Cancer Biology and the Mutant Mouse: Am. Assoc. Cancer Res. Keystone Conference (Abstr./Poster) Feb. 1999.
• Bok, R.A., and Small, E.J. (1999) Bok, RA; Small, EJ. The Treatment of Advanced Prostate Cancer with Ketoconazole: Safety Issues. Drug Safety 20(5):451-8.
• Small, E.J., Frohlich, M.W., Bok, R., Shinohara, K., Grossfeld, G., Rozenblat, Z., Kelly, W.K., Corry, M., and Reese, D.M. (2000) Prospective Trial of the Herbal Supplement PC-SPES in Patients with Progressive Prostate Cancer. J. Clin. Oncol. 18(21):3595-3603.
• Bok, R.A., Small, E.J., Curnow, R., Roach, M., Carroll, P., Kivitz, S., Frohlich, M.W. CD4 and CD8 Counts are Suppressed in Patients with Advanced Prostate Cancer Treated with Chemotherapy or Radiation Therapy. Am. Soc. Clin. Oncol. Proc. (Abstr.), May 2001 National Meeting.
• Bok, R.A., Halabi, S., Fei, D.T., Rodriquez, C.R., Hayes, D.F., Vogelzang, N.J., Kantoff, P., Shuman, M.A., and Small, E.J. (2001) Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-Refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study. Cancer Res. 61: 2533-2536.
• Bok, R.A., Hansell, E., Nguyen, T., Greenberg, N., McKerrow, J., Shuman, M. (2001) Extracellular Proteases in Prostate Cancer Progression: Functional Proteomic Analysis in the TRAMP Model for Adenocarcinoma of the Prostate. (Manuscript submitted, Cancer Research).
• Elfman, F., Sun, J., Bok, R., Conn, M., Craik, C., Shuman, M. Dissemination of Human Prostate Cancer Cells is Reduced by Selective Protease Inhibition. (Manuscript in preparation.)
• Elfman, F., Bok, R., Conn, M., Shuman, M., Cunha, G. (2001) Urokinase Plasminogen Activator Amino-Terminal Peptides Inhibit Development of the Rat Ventral Prostate. Differentiation (publication pending).